Protocol Ledger

NCT06864988 · Phase III · ACTIVE NOT RECRUITING

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Interventional Phase III clinical trial protocol NCT06864988 sponsored by 4D Molecular Therapeutics in Ophthalmology and Sensory, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-03 Enrollment: 480 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06864988
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)480 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06864988
Protocol FieldVerified Registry Value
NCT IdentifierNCT06864988
Consolidated Lead Sponsor4D Molecular Therapeutics
Therapeutic Condition CohortOphthalmology and Sensory
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment480 participants (ESTIMATED)
Registered Start Date2025-03-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06864988
Hospital Research SiteLocationSite Profile
California Retina ConsultantsBakersfield, CAOpen Hospital Dossier ->
Retina Vitreous Associates Medical GroupBeverly Hills, CAOpen Hospital Dossier ->
The Retina PartnersEncino, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Ophthalmology and Sensory Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI